Key facts
- Cellarity’s last known valuation is $525.0M (Dec 2024).
- It has raised $519.3M; the latest was Later Stage VC ($195.0M) in Dec 2024.
- Notable investors include BlackRock, Flagship Pioneering, Pictet, Hanwha Impact, The Baupost Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Cellarity
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellarity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellarity
Developer of a biomedical platform designed to digitize the molecular information in cells to elucidate how they behave in health and disease. The company's platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them, enabling companies to increase drug discovery's success rate and speed.
- Sector
- Healthcare
- HQ
- Somerville, MA, United States
- Founded
- 2019
- Employees
- 88
- Website
- cellarity.com/
- Ownership
- Privately Held (backing)
Cellarity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellarity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellarity in its N-PORT filings yet. We sweep new filings monthly.